In brief
On November 1, 2026, Canberra‑based Health Minister Mark Butler announced that the Pharmaceutical Benefits Scheme would list a child‑friendly form of Trikafta for cystic fibrosis, Tepezza for thyroid eye disease, an expanded first‑line use of Adcetris for Hodgkin lymphoma, and larger dispensing limits for Repatha. The changes are expected to benefit thousands of Australians each year and are part of a broader effort that has added 511 PBS listings since July 2022. The plan’s true impact remains uncertain, as uptake, eligibility, and long‑term costs have yet to be fully assessed.
On November 1, 2026, the Australian government widened subsidised medicine access under the Pharmaceutical Benefits Scheme (PBS) and announced the expansion in Canberra, with Health Minister Mark Butler addressing the public on the newly broadened listings.
Under the new rule, children aged six to 11 who weigh under 30 kg will receive a granule formulation of Trikafta, a drug that targets the underlying genetic defect of cystic fibrosis. The child‑friendly version is designed to help youngsters who struggle to swallow tablets, a key barrier that previously limited many families from using the medicine. Government officials estimate that about 3,300 Australians could benefit from the updated listing each year, a figure driven by the number of children who meet the weight and age criteria.
The PBS has also added Tepezza to treat active, moderate‑to‑severe thyroid eye disease. The drug, known for its ability to reduce inflammation in affected eyes, could enable around 310 Australians yearly to receive the treatment through government subsidy. This addition follows a shortage of approved therapies for patients whose visual and eye‑muscle function are compromised.
Adcetris, a biologic used for blood cancer therapy, is no longer restricted to second‑line use. The revised PBS entry allows it to serve as a first‑line treatment for patients with advanced CD30‑positive classical Hodgkin lymphoma, expanding coverage to roughly 370 Australians each year. The move signals a shift toward earlier intervention for this type of blood cancer.
The scheme’s treatment for high cholesterol has also been altered. Repatha is now listed with a 60‑day prescription option, permitting patients to obtain larger quantities in a single dispensing. Eligible patients are required to pay a maximum of 25 Australian dollars per prescription, or only 7.70 dollars for concession card holders. The adjustment reflects a broader strategy to reduce out‑of‑pocket expense for chronic medication users.
Collectively, the government stated that it had approved 511 new or amended PBS listings between July 2022 and the current announcement. The broad range of added medications represents an expansion of the PBS’s reach into several disease areas that previously had limited subsidised options.
While each individual listing claims to benefit a sizable subgroup, the research and reporting have yet to quantify actual patient uptake, regional disparities, or the exact cost savings projected for the Australian health budget. Data on how many patients will enroll, whether clinicians will prescribe the new formulations, and how the price points affect long‑term healthcare spending remain to be determined. The government’s official communications in this announcement note that “expected” figures are provisional and that real‑world application may shift based on a number of variables, including prescriber practices and patient preferences.
At this juncture, the exact details of the program’s effectiveness, such as the number of patients who will ultimately receive the subsidised drugs, the long‑term economic impact on the public health system, and the potential for unintended consequences, have not been disclosed. An ongoing review of programme outcomes is therefore required to determine whether the PBS expansions achieve the intended benefits for the Australian public.
